Red blood cell distribution width-to-monocyte ratio for predicting 90-day mortality of COVID-19 in patients with chronic kidney disease during the Omicron period: a prospective single-center study

We aimed to test whether red blood cell distribution width (RDW) to monocyte percentage ratio (RMR) was associated with the acute-phase prognosis of coronavirus disease 2019 (COVID-19) in chronic kidney disease (CKD) patients. Prospective enrollment and 90-day follow-up of CKD patients with COVID-19...

Full description

Saved in:
Bibliographic Details
Main Authors: Chaofan Li, Yue Niu, Dinghua Chen, Zhe Feng, Fei Liu, Yong Wang, Xueying Cao, Jie Wu, Jiabao Liu, Xuefeng Sun, Li Zhang, Guangyan Cai, Ping Li, Xiangmei Chen
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Renal Failure
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/0886022X.2024.2387933
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849688447300665344
author Chaofan Li
Yue Niu
Dinghua Chen
Zhe Feng
Fei Liu
Yong Wang
Xueying Cao
Jie Wu
Jiabao Liu
Xuefeng Sun
Li Zhang
Guangyan Cai
Ping Li
Xiangmei Chen
author_facet Chaofan Li
Yue Niu
Dinghua Chen
Zhe Feng
Fei Liu
Yong Wang
Xueying Cao
Jie Wu
Jiabao Liu
Xuefeng Sun
Li Zhang
Guangyan Cai
Ping Li
Xiangmei Chen
author_sort Chaofan Li
collection DOAJ
description We aimed to test whether red blood cell distribution width (RDW) to monocyte percentage ratio (RMR) was associated with the acute-phase prognosis of coronavirus disease 2019 (COVID-19) in chronic kidney disease (CKD) patients. Prospective enrollment and 90-day follow-up of CKD patients with COVID-19 were conducted from December 1, 2022 to January 31, 2023. Demographics, clinical data, and laboratory and radiographic findings were collected, and multiple logistic regression, subgroup analysis, and receiver operating characteristic (ROC) curve analysis were performed. A total of 218 patients were enrolled, with a mean age of 59 years and 69.7% being male. The 90-day mortality rate was 24.8%. The lnRMR level was 5.18 (4.91-5.43) and emerged as an independent risk factor (OR: 3.01, 95% CI: 1.72-5.85). The lnRMR-mortality association was consistent across sex, age, CKD stage, COVID-19 vaccination, and comorbidity subgroups. The area under the ROC curve of lnRMR was 0.737 (95% CI: 0.655-0.819). Our findings indicate that lnRMR is a simple and practical predictor for identifying high-risk CKD patients during the acute phase of COVID-19.
format Article
id doaj-art-614fe82f3eeb4922a9d0aad85aee8791
institution DOAJ
issn 0886-022X
1525-6049
language English
publishDate 2024-12-01
publisher Taylor & Francis Group
record_format Article
series Renal Failure
spelling doaj-art-614fe82f3eeb4922a9d0aad85aee87912025-08-20T03:22:00ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492024-12-0146210.1080/0886022X.2024.2387933Red blood cell distribution width-to-monocyte ratio for predicting 90-day mortality of COVID-19 in patients with chronic kidney disease during the Omicron period: a prospective single-center studyChaofan Li0Yue Niu1Dinghua Chen2Zhe Feng3Fei Liu4Yong Wang5Xueying Cao6Jie Wu7Jiabao Liu8Xuefeng Sun9Li Zhang10Guangyan Cai11Ping Li12Xiangmei Chen13Department of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases Research, Beijing, ChinaDepartment of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases Research, Beijing, ChinaDepartment of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases Research, Beijing, ChinaDepartment of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases Research, Beijing, ChinaDepartment of Urology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases Research, Beijing, ChinaDepartment of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases Research, Beijing, ChinaDepartment of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases Research, Beijing, ChinaDepartment of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases Research, Beijing, ChinaDepartment of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases Research, Beijing, ChinaDepartment of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases Research, Beijing, ChinaDepartment of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases Research, Beijing, ChinaDepartment of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases Research, Beijing, ChinaDepartment of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases Research, Beijing, ChinaWe aimed to test whether red blood cell distribution width (RDW) to monocyte percentage ratio (RMR) was associated with the acute-phase prognosis of coronavirus disease 2019 (COVID-19) in chronic kidney disease (CKD) patients. Prospective enrollment and 90-day follow-up of CKD patients with COVID-19 were conducted from December 1, 2022 to January 31, 2023. Demographics, clinical data, and laboratory and radiographic findings were collected, and multiple logistic regression, subgroup analysis, and receiver operating characteristic (ROC) curve analysis were performed. A total of 218 patients were enrolled, with a mean age of 59 years and 69.7% being male. The 90-day mortality rate was 24.8%. The lnRMR level was 5.18 (4.91-5.43) and emerged as an independent risk factor (OR: 3.01, 95% CI: 1.72-5.85). The lnRMR-mortality association was consistent across sex, age, CKD stage, COVID-19 vaccination, and comorbidity subgroups. The area under the ROC curve of lnRMR was 0.737 (95% CI: 0.655-0.819). Our findings indicate that lnRMR is a simple and practical predictor for identifying high-risk CKD patients during the acute phase of COVID-19.https://www.tandfonline.com/doi/10.1080/0886022X.2024.2387933Chronic kidney diseaseCOVID-19prognosisred blood cell distribution widthmonocyte
spellingShingle Chaofan Li
Yue Niu
Dinghua Chen
Zhe Feng
Fei Liu
Yong Wang
Xueying Cao
Jie Wu
Jiabao Liu
Xuefeng Sun
Li Zhang
Guangyan Cai
Ping Li
Xiangmei Chen
Red blood cell distribution width-to-monocyte ratio for predicting 90-day mortality of COVID-19 in patients with chronic kidney disease during the Omicron period: a prospective single-center study
Renal Failure
Chronic kidney disease
COVID-19
prognosis
red blood cell distribution width
monocyte
title Red blood cell distribution width-to-monocyte ratio for predicting 90-day mortality of COVID-19 in patients with chronic kidney disease during the Omicron period: a prospective single-center study
title_full Red blood cell distribution width-to-monocyte ratio for predicting 90-day mortality of COVID-19 in patients with chronic kidney disease during the Omicron period: a prospective single-center study
title_fullStr Red blood cell distribution width-to-monocyte ratio for predicting 90-day mortality of COVID-19 in patients with chronic kidney disease during the Omicron period: a prospective single-center study
title_full_unstemmed Red blood cell distribution width-to-monocyte ratio for predicting 90-day mortality of COVID-19 in patients with chronic kidney disease during the Omicron period: a prospective single-center study
title_short Red blood cell distribution width-to-monocyte ratio for predicting 90-day mortality of COVID-19 in patients with chronic kidney disease during the Omicron period: a prospective single-center study
title_sort red blood cell distribution width to monocyte ratio for predicting 90 day mortality of covid 19 in patients with chronic kidney disease during the omicron period a prospective single center study
topic Chronic kidney disease
COVID-19
prognosis
red blood cell distribution width
monocyte
url https://www.tandfonline.com/doi/10.1080/0886022X.2024.2387933
work_keys_str_mv AT chaofanli redbloodcelldistributionwidthtomonocyteratioforpredicting90daymortalityofcovid19inpatientswithchronickidneydiseaseduringtheomicronperiodaprospectivesinglecenterstudy
AT yueniu redbloodcelldistributionwidthtomonocyteratioforpredicting90daymortalityofcovid19inpatientswithchronickidneydiseaseduringtheomicronperiodaprospectivesinglecenterstudy
AT dinghuachen redbloodcelldistributionwidthtomonocyteratioforpredicting90daymortalityofcovid19inpatientswithchronickidneydiseaseduringtheomicronperiodaprospectivesinglecenterstudy
AT zhefeng redbloodcelldistributionwidthtomonocyteratioforpredicting90daymortalityofcovid19inpatientswithchronickidneydiseaseduringtheomicronperiodaprospectivesinglecenterstudy
AT feiliu redbloodcelldistributionwidthtomonocyteratioforpredicting90daymortalityofcovid19inpatientswithchronickidneydiseaseduringtheomicronperiodaprospectivesinglecenterstudy
AT yongwang redbloodcelldistributionwidthtomonocyteratioforpredicting90daymortalityofcovid19inpatientswithchronickidneydiseaseduringtheomicronperiodaprospectivesinglecenterstudy
AT xueyingcao redbloodcelldistributionwidthtomonocyteratioforpredicting90daymortalityofcovid19inpatientswithchronickidneydiseaseduringtheomicronperiodaprospectivesinglecenterstudy
AT jiewu redbloodcelldistributionwidthtomonocyteratioforpredicting90daymortalityofcovid19inpatientswithchronickidneydiseaseduringtheomicronperiodaprospectivesinglecenterstudy
AT jiabaoliu redbloodcelldistributionwidthtomonocyteratioforpredicting90daymortalityofcovid19inpatientswithchronickidneydiseaseduringtheomicronperiodaprospectivesinglecenterstudy
AT xuefengsun redbloodcelldistributionwidthtomonocyteratioforpredicting90daymortalityofcovid19inpatientswithchronickidneydiseaseduringtheomicronperiodaprospectivesinglecenterstudy
AT lizhang redbloodcelldistributionwidthtomonocyteratioforpredicting90daymortalityofcovid19inpatientswithchronickidneydiseaseduringtheomicronperiodaprospectivesinglecenterstudy
AT guangyancai redbloodcelldistributionwidthtomonocyteratioforpredicting90daymortalityofcovid19inpatientswithchronickidneydiseaseduringtheomicronperiodaprospectivesinglecenterstudy
AT pingli redbloodcelldistributionwidthtomonocyteratioforpredicting90daymortalityofcovid19inpatientswithchronickidneydiseaseduringtheomicronperiodaprospectivesinglecenterstudy
AT xiangmeichen redbloodcelldistributionwidthtomonocyteratioforpredicting90daymortalityofcovid19inpatientswithchronickidneydiseaseduringtheomicronperiodaprospectivesinglecenterstudy